A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination with Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas

ID Number 13-1347

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and anti-lymphoma effects of a combining a standard therapy -low dose irradiation of one site of lymphoma- with two experimental medicines called 'Flt3L/CDX-301' and 'poly-ICLC' which will be injected directly into the same site of lymphoma.  When a lymphocyte (a type of white blood cell) becomes cancerous, it grows and multiplies to form a lymphoma.  The treatments given in this study are intended to stimulate the body’s immune system to learn to recognize and then to destroy the cancer. 


Contact Information
(212) 824-7309

Recruiting Patients: Yes